NDC product
Exforge HCT
NDC 0078-0563 · Novartis Pharmaceuticals Corporation
Key facts
| Product NDC | 0078-0563 |
|---|---|
| Proprietary name | Exforge HCT |
| Nonproprietary name | amlodipine valsartan and hydrochlorothiazide |
| Substances | AMLODIPINE BESYLATE, VALSARTAN, HYDROCHLOROTHIAZIDE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Novartis Pharmaceuticals Corporation |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA022314 |
| Pharmacologic classes | Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC] and 4 more |
| Marketing start | Apr 4, 2009 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: